GSK is to stop paying doctors to talk about its drugs and attend conferences
BMJ 2014; 347 doi: https://doi.org/10.1136/bmj.f7579 (Published 03 January 2014) Cite this as: BMJ 2014;347:f7579
This article has a correction. Please see:
- Zosia Kmietowicz
- 1BMJ
The UK based pharmaceutical giant GlaxoSmithKline has said that by the start of 2016 it will stop paying doctors to speak on its behalf or to attend conferences, to end undue influence on prescribers.
In an announcement on 17 December GSK also said that it planned to remove individual sales targets from its sales force, meaning that drug representatives would no longer be paid according to the number of prescriptions they solicited from the doctors they saw.
Instead GSK is introducing a new performance related scheme that will reward sales representatives for their technical knowledge, the quality of the service they deliver to support improved care of patients, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.